isr - ISR STOCK NEWS

Isoray (NYSE: ISR) reported a 10% sequential increase in revenue for Q3 fiscal 2021, totaling $2.60 million, despite a 10% decline year-over-year. Core prostate brachytherapy revenue fell 16% compared to last year but showed 7% growth sequentially. Non-prostate brachytherapy revenue rose 20% year-over-year, driven by treatments for brain and lung cancers. Gross profit decreased 20% to $1.36 million, yielding a 52.4% margin. Operating expenses fell 6%, while the net loss stood at $0.75 million, unchanged from last year. Cash reserves reached $64.8 million.

Isoray (NYSE AMERICAN: ISR) announced a conference call on May 13, 2021, at 4:30 p.m. ET to discuss its Q3 fiscal 2021 financial results, ending March 31, 2021. The company will release its financial results following the market close on the same day. Investors can join the call by dialing 877-407-8035 (U.S.) or 201-689-8035 (international). A webcast will be available at this link and will remain accessible until August 13, 2021.

Isoray, Inc. (NYSE American: ISR) announced the appointment of Donna Fort as Vice President of Sales and Marketing, bringing over 25 years of experience in oncology and sales leadership. CEO Lori Woods expressed excitement about Fort’s ability to drive revenue and expand the company's Cesium-131 brachytherapy treatment applications. Fort previously held executive roles at Sirtex Medical and Johnson & Johnson, enhancing operational efficiencies in cancer treatment across multiple regions. The company also acknowledged the departure of former SVP Michael Krachon.

Isoray's recent study at the University Hospitals Cleveland Medical Center reveals promising results for treating recurrent head and neck cancers using Cesium-131 brachytherapy combined with surgical resection. The study, involving 12 patients, demonstrated that this approach is safe and feasible, potentially reducing radiation side effects compared to external beam radiation therapy. Key findings showed a low recurrence rate within the Cesium-131 implant area and overall survival rates similar to prolonged external beam treatments, highlighting the need for further research into combining this therapy with immunotherapy.

Isoray, a medical technology company specializing in seed brachytherapy, announced that CEO Lori Woods will present at the Oppenheimer 31st Annual Healthcare Conference on March 17 at 11:20 a.m. ET. She will be joined by CFO Jonathan Hunt for virtual meetings with institutional investors during the event. A live webcast of the presentation will be available on Isoray's Investor Relations website, with an on-demand replay accessible for 90 days after the event. Isoray is the sole producer of Cesium-131 brachytherapy seeds, aimed at enhancing treatment options.

Isoray, Inc. (NYSE American: ISR) has appointed Lisa Lauer as Vice President, Business Development. Lauer brings over 27 years of extensive experience in the medical technology sector, particularly in cancer treatment. CEO Lori Woods emphasized Lauer's industry expertise and strategic insight, enhancing the company's growth in prostate and other cancer treatments. Lauer's previous role involved significant contributions at Olympus Corporation and a return to Isoray after her time in marketing from 2005 to 2009.

Isoray, Inc. (NYSE AMERICAN: ISR) reported a 7% increase in revenue year-over-year for Q2 FY2021, reaching $2.36 million. Non-prostate brachytherapy revenue surged 92% primarily due to sales for brain cancer treatments, while prostate brachytherapy revenue fell 4%, accounting for 80% of total revenue. The net loss decreased 3% to $0.87 million. Gross profit rose 5% to $1.17 million. The company announced a public offering, raising approximately $51.75 million from the sale of 41.4 million shares.

Isoray, Inc. (NYSE AMERICAN: ISR) will host a conference call on February 9, 2021, at 4:30 p.m. ET to discuss its financial results for Q2 FY 2021, which ended on December 31, 2020. A press release with the financial results will be issued after the market close on the same day. The conference call can be accessed via phone or a live webcast, which will remain available until May 9, 2021. Isoray is recognized for its innovation in brachytherapy, specifically in the production of Cesium-131 seeds.

Isoray, Inc. (NYSE AMERICAN: ISR) has announced a public offering of 36 million shares of common stock priced at $1.25 per share, aiming to raise approximately $45 million before expenses. The funds are designated for operational costs, research and development, acquisitions, marketing initiatives, and general corporate purposes. The offering is set to close on February 8, 2021, pending customary conditions. Oppenheimer & Co. is the lead manager, with additional co-managers involved. The shares are offered under a previously effective "shelf" registration statement.